Clinical and economic evidence thresholds for orphan drugs- Are requirements for favorable health technology assessment and reimbursement on the rise?
May 1, 2013, 00:00 AM
10.1016/j.jval.2013.03.512
https://www.valueinhealthjournal.com/article/S1098-3015(13)00583-4/fulltext
Section Title :
Neurological Disorders
Section Order :
54
First Page :
A108
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)00583-4&doi=10.1016/j.jval.2013.03.512